Log in to save to my catalogue

Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multice...

Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multice...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11592128

Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study

About this item

Full title

Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study

Publisher

Switzerland: MDPI AG

Journal title

Cancers, 2024-11, Vol.16 (22), p.3779

Language

English

Formats

Publication information

Publisher

Switzerland: MDPI AG

More information

Scope and Contents

Contents

Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with a significant percentage of germline pathogenic variants (GPVs). Unlike in the United States, routine universal genetic testing is not performed in Europe. The aim of the study is to evaluate the diagnostic yield of germline genetic testing in all patients with PDAC. Methods: In...

Alternative Titles

Full title

Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11592128

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11592128

Other Identifiers

ISSN

2072-6694

E-ISSN

2072-6694

DOI

10.3390/cancers16223779

How to access this item